Compare ARCO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | MESO |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | Uruguay | Australia |
| Employees | N/A | 81 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | MESO |
|---|---|---|
| Price | $8.66 | $14.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.60 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 152.9K |
| Earning Date | 05-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | $629.74 |
| Revenue Next Year | $3.48 | $30.65 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $9.88 |
| 52 Week High | $9.75 | $21.50 |
| Indicator | ARCO | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 39.73 |
| Support Level | $8.51 | $14.15 |
| Resistance Level | $8.98 | $16.31 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 14.63 | 7.45 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.